Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY011 in Advanced Gastric Adenocarcinoma
NCT04977193Phase 1Unknown
- Sponsor
- Shanghai Longyao Biotechnology Co., Ltd.
- Start
- Nov 2021
- Primary completion
- May 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LY011 in gastric adenocarcinoma, sponsored by Shanghai Longyao Biotechnology Co., Ltd. Primary endpoints: Maximum Tolerable Dose at 1 month and Incidence of Treatment-Emergent Adverse Events at 2 years. Status: unknown.
02
Drugs
LY011
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04977193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04977193.